5 min read

Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund

Funds to support advancement of SF001, a next-generation polyene antifungal designed for reduced toxicity

Written by

Published on

Updated on

June 17, 2024

Share this post